| Current Price | $23.48 | Mkt Cap | $494.4M |
|---|---|---|---|
| Open | $23.92 | P/E Ratio | -3.92 |
| Prev. Close | $23.48 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $22.80 - $24.97 | Volume | 569,049 |
| 52-Wk Range | $22.80 - $76.36 | Avg. Daily Vol. | 199,699 |
| Current Price | $23.48 | Mkt Cap | $494.4M |
|---|---|---|---|
| Open | $23.92 | P/E Ratio | -3.92 |
| Prev. Close | $23.48 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $22.80 - $24.97 | Volume | 569,049 |
| 52-Wk Range | $22.80 - $76.36 | Avg. Daily Vol. | 199,699 |
The best Bull and Bear pitches based on recency and number of recommendations.
Royalty stream from abbvie likely significant. tiny company with 44 employees and low cash burn rate. Hep C drug looks like it works. They won't be first to market, but probably will have impact.
There are no pitches that meet the Top Bear criteria. Explain
If this upsets you, start recommending pitches below!
Read the most recent pitches from players about ENTA.
Recs
Thrifty1
(< 20)
Submitted: 4/12/2014 11:17:34 PM :
Start Price:
$33.99
NASDAQ:ENTA Score:
-159.06
Royalty stream from abbvie likely significant. tiny company with 44 employees and low cash burn rate. Hep C drug looks like it works. They won't be first to market, but probably will have impact.
Recs
dbajack2
(84.80)
Submitted: 2/10/2014 4:06:30 PM :
Start Price:
$38.28
NASDAQ:ENTA Score:
-170.31
About to break resistance.
Recs
PharmTeam
(57.15)
Submitted: 12/18/2013 10:29:23 AM :
Start Price:
$30.66
NASDAQ:ENTA Score:
-156.66
Enanta's collaboration with Abbvie on a next gen HepC treatment is clearly its main growth driver. That drug will face some serious competition from Gilead's Sovaldi, but with pretty comparable cure rates it will be up to payers to decide which drug to go with. Gilead's solid results today sent ENTA down 14% to a market cap of only 500M and change, making for a good entry point.
Find the members with the highest scoring picks in ENTA.
fredvaldez88 (< 20) Score: +262.24
The Score Leader is the player with the highest score across all their picks in ENTA.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| CocaineOrStock | 94.62 | 7/15/2014 |
|
5Y | $38.88 | -39.61% | +111.49% | +151.10 | 0 Comment | |
| PeakingDuck | 78.89 | 6/27/2019 |
|
5Y | $83.38 | -71.84% | +43.09% | +114.93 | 0 Comment | |
| sikiliza | < 20 | 10/28/2019 |
|
5Y | $59.36 | -60.44% | +37.76% | +98.21 | 0 Comment | |
| stereotyp72 | 69.38 | 4/5/2021 |
|
5Y | $51.20 | -54.14% | +3.44% | -57.58 | 0 Comment | |
| portefeuille4 | 98.76 | 9/2/2016 |
|
5Y | $22.12 | +6.17% | +91.36% | -85.19 | 0 Comment | |
| superstar2 | 98.57 | 7/6/2016 |
|
5Y | $23.19 | +1.25% | +99.37% | -98.12 | 0 Comment | |
| RonaldSpeth1 | 55.72 | 10/25/2016 |
|
5Y | $24.93 | -5.82% | +94.38% | -100.20 | 0 Comment | |
| TMFConan | 84.99 | 10/3/2016 |
|
5Y | $26.60 | -11.73% | +93.37% | -105.10 | 0 Comment | |
| Momentum21 | 51.46 | 1/31/2017 |
|
5Y | $32.83 | -28.48% | +84.24% | -112.72 | 0 Comment | |
| bmasc23 | 60.02 | 1/17/2018 |
|
5Y | $63.24 | -62.87% | +50.11% | -112.98 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
